The largest community of pharma leaders

Genus plc to Announce Preliminary 2020 Year End Financial and Business Results on September 8, 2020

BASINGSTOKE, United Kingdom & MADISON, Wis.–()–Genus plc (LSE: GNS), a world leading animal genetics company producing superior breeding livestock through genetic improvement, today announced that it will release its preliminary financial results for the full year ended June 30, 2020, and provide a business update on recent corporate developments in its worldwide porcine and bovine genetics businesses, on Tuesday, September 8, 2020.

Webcast Results Presentation

A pre-recorded briefing by management to discuss the preliminary results for the year ended June 30, 2020 will be held via a video webcast facility and will be accessible at the following link beginning at 7:01 AM BST, 1:01 AM EDT on September 8th: https://webcasting.buchanan.uk.com/broadcast/5f28011c65023062edd7e24a.

An archived recording of the webcast will also be available on the Investors section of the Company’s website.

About Genus

Genus advances animal breeding and genetic improvement by applying biotechnology and sells added value products for livestock farming and food producers. Its technology is applicable across livestock species and is currently commercialised by Genus in the dairy, beef and pork food production sectors.

Genus’s worldwide sales are made in over 75 countries under the trademarks ‘ABS’ (dairy and beef cattle) and ‘PIC’ (pigs) and comprise semen, embryos and breeding animals with superior genetics to those animals currently in farms. Genus’s customers’ animals produce offspring with greater production efficiency and quality, and our customers use them to supply the global dairy and meat supply chains.

Genus’s competitive edge comes from the ownership and control of proprietary lines of breeding animals, the biotechnology used to improve them and its global supply chain, technical service and sales and distribution network.

Headquartered in Basingstoke, United Kingdom, Genus companies operate in over 25 countries on six continents, with research laboratories located in Madison, Wisconsin, USA.

Source

Recent Articles

Gyroscope Therapeutics Granted FDA Fast Track Designation for GT005, an Investigational Gene Therapy for Dry Age-Related Macular Degeneration

LONDON--(BUSINESS WIRE)-- #GeneTherapy--Gyroscope Therapeutics Granted FDA Fast Track Designation for GT005,...

Medeor Therapeutics’ Transplant Immune Tolerance Therapy Receives Regenerative Medicine Advanced Therapy Designation from FDA

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Medeor announces that the FDA has granted...

FDA Sued for Ignoring Petition Calling for Breast Cancer Warning Labels on Cheese

WASHINGTON--(BUSINESS WIRE)--The Physicians Committee for Responsible Medicine filed a lawsuit on...
2020 Call for Writers

Are you looking to inspire others in the pharma industry through your writing? You’re invited to submit your articles to become a Featured Writer for The Pharmaceutical Marketing Group website.